Why Promising Pilot Results Frequently Disappear in Later Trials Executive Summary Early clinical studies frequently produce encouraging results that fail to reproduce in larger trials. This phenomenon is often attributed to biological complexity, patient heterogeneity, or chance. While these factors contribute, they do not fully explain the consistency of the pattern. Across therapeutic areas, small studies systematically overestimate treatment effects. The issue is not rand

Executive Summary Modern drug development successfully produces therapies that meet regulatory standards of efficacy and safety. Yet a substantial proportion of approved interventions fail to achieve meaningful adoption within healthcare systems. The failure is sometimes about pharmacological efficacy, but other times it is about a lack of convincing evidence. Clinical trials are designed to establish causal effect under controlled conditions. Healthcare systems must decide w

Why Clinical Success Does Not Guarantee Program Continuation Executive Summary In drug development, failure is visible and success is assumed to be decisive. But across biotech and pharmaceutical portfolios, a growing category of assets enters an in-between state of positive but unusable. In this s tate, the study meets its primary endpoint and regulators accept the data; yet, the program stalls, loses investment priority, or fails commercially. Modern development programs